Therapeutic drug monitoring of letermovir in allogeneic hematopoietic cell transplant recipients: where are we? (PubMed, Expert Opin Drug Metab Toxicol) - Mar 6, 2026 - "Randomized controlled trials are needed to determine the clinical benefit of letermovir TDM in HSCT recipients. Furthermore, studies are warranted to characterize letermovir pharmacokinetics in situations encountered in clinical practice (complex drug-drug interactions and/or organ dysfunction) and to determine letermovir optimal dosing in the pediatric population."
Journal • Review • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Pediatrics • Transplantation
|
|
Catia Marzolini; Dela Wordi; Françoise Livio; Hong-Tham Nguyen; Marta Boffito; Oriol Manuel
|